COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

RNA vaccines have been a long time coming, but were only approved after covid-19 emerged, marking the beginning of a new way ...

Engineers have developed a lipid nanoparticle (LNP) that delivers mRNA therapeutic ... the delivery molecules that helped get the mRNA of the COVID vaccine into cells, and their ability to reach ...

Penn Engineers have modified lipid nanoparticles (LNPs)—the revolutionary technology behind the COVID-19 mRNA vaccines—to not ...

The vaccine – developed by researchers at the University of Florida (UF) in the US – is based on mRNA taken from the patient’s tumour that is delivered in a lipid nanoparticle (LNP ...

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

Billions of Covid vaccine doses have been safely administered globally since 2021 but misinformation about the jabs persists.

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.